MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$36,935,000
EPS
-$0.83
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues, net-Product
-
-
-
0
Total revenues, net
-
-
59,000*
0
Cost of product sales
-
-
0*
0
Research and development
23,418,000
14,047,000
8,541,500*
13,621,000
Acquired in-process research and development
-
-
0*
0
General and administrative
8,099,000
6,854,000
6,671,500*
5,577,000
Total operating expenses
31,517,000
20,901,000
15,213,000*
19,198,000
Loss from operations
-31,517,000
-20,901,000
-15,154,000*
-19,198,000
Change in fair value of derivative liability
-1,010,000
480,000
13,082,000*
12,530,000
Change in fair value of contingent consideration
6,574,000
-
-
-
Interest income, net
2,761,000
803,000
1,022,500*
1,117,000
Excess of initial warrant fair value over private placement proceeds
-
-
0*
0
Change in fair value of warrant liability
-
-
0*
0
Private placement transaction costs
-
-
0*
0
Other expense, net
-
-
-
-3,000
Total other (expense) income, net
-4,823,000
1,283,000
14,104,500*
-11,416,000
Loss before taxes
-36,340,000
-19,618,000
-1,049,500*
-30,614,000
Income tax expense
18,000
12,000
124,500*
11,000
Net loss
-36,358,000
-19,630,000
-1,174,000*
-30,625,000
Unrealized loss on investments, net
-577,000
-74,000
6,500*
75,000
Comprehensive loss
-36,935,000
-19,704,000
-1,167,500
-30,550,000
Basic EPS
-0.83
-0.98
-0.076
-2.19
Diluted EPS
-0.83
-0.98
-0.076
-2.19
Basic Average Shares
43,602,044
20,106,925
15,384,279
14,000,451
Diluted Average Shares
43,602,044
20,106,925
15,384,279
14,000,451
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$36,935,000
(-77.58%↓ Y/Y)
Net loss
-$36,358,000
(-75.09%↓ Y/Y)
Unrealized loss on
investments, net
-$577,000
(-1597.06%↓ Y/Y)
Loss before taxes
-$36,340,000
(-75.14%↓ Y/Y)
Income tax expense
$18,000
(12.50%↑ Y/Y)
Loss from operations
-$31,517,000
(-63.17%↓ Y/Y)
Total other (expense)
income, net
-$4,823,000
(-236.57%↓ Y/Y)
Interest income, net
$2,761,000
(150.54%↑ Y/Y)
Total operating
expenses
$31,517,000
(63.17%↑ Y/Y)
Change in fair value of
contingent consideration
$6,574,000
Change in fair value of
derivative liability
-$1,010,000
(-139.92%↓ Y/Y)
Research and development
$23,418,000
(66.39%↑ Y/Y)
General and
administrative
$8,099,000
(54.50%↑ Y/Y)
Buy us a coffee
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)